ShK-186 is the first autoimmune drug to enter into the clinic, to develop an immune-sparing therapy for diseases like Multiple Sclerosis (MS), Rheumatoid Arthritis and Lupus, according to
ThermoGenesis has received the $2m cash payment from Asahi associated with the sale of the CryoSeal Fibrin Sealant System to Asahi. ThermoGenesis chief executive officer Matthew Plavan said
The multi-centred, placebo controlled study measured the prophylactic effect of the two dosage regimes against influenza infection against placebo and the protective efficacy calculated. Compared to placebo, Inavir
Xyntek is involved in providing real-time automated IT systems and microprocessor based industrial automation solutions to the life sciences industries. Xyntek president and CEO Mac Hashemian said the
The service will aid in the development of molecular tests for trial enrichment and companion diagnostic development, focussing on targeted re-sequencing. Almac Diagnostics business unit president and managing
The anti-tumor technology consists of methods for isolation and propagation of the primary human cells, gene profiles obtained from the cells identifying candidate micro RNAs and growth factor
Upon closing of the acquisition, Biochrom’s operations will be maintained in Berlin while its activities will be part of Merck Millipore’s Process Solutions business unit. The acquisition, which
The new Beijing facility is expected to enhance PRA local project teams’ ability in meeting the growing demand for its clinical drug development programs and also to collocate
Heplisav is indicated for immunization against infection caused by all known subtypes of hepatitis B virus in people aged 18 through 70 years of age and in patients
Gevokizumab (XOMA 052) is a potent monoclonal antibody that strongly binds to interleukin-1 beta (IL-1 beta) and possesses allosteric modulating properties capable of treating patients suffering from a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.